Lenvatinib

Definition

A synthetic, orally available inhibitor of vascular endothelial growth factor receptor 2 (VEGFR2, also known as KDR/FLK-1) tyrosine kinase with potential antineoplastic activity. Lenvatinib blocks VEGFR2 activation by VEGF, resulting in inhibition of the VEGF receptor signal transduction pathway, decreased vascular endothelial cell migration and proliferation, and vascular endothelial cell apoptosis.

Also known as 6-Quinolinecarboxamide, 4-[3-chloro-4-[[(cyclopropylamino)carbonyl]amino]phenoxy]- 7-methoxy-, E 7080, E-7080, E7080, ER-203492-00, LENVATINIB, Multi-Kinase Inhibitor E7080 — per NCIT

Also identified as

• ATC L01EX08 per RXNORM
• NCIT NCIT:C95124 per NCIT
• SCTID 714108002 per RXNORM
• SCTID 714109005 per RXNORM
• UNII EE083865G2 per RXNORM

Indications